Monte Rosa Therapeutics, Inc. (GLUE): Price and Financial Metrics
GET POWR RATINGS... FREE!
GLUE Stock Price Chart Interactive Chart >
GLUE Price/Volume Stats
| Current price | $8.10 | 52-week high | $45.56 |
| Prev. close | $7.78 | 52-week low | $7.19 |
| Day low | $7.53 | Volume | 126,400 |
| Day high | $8.22 | Avg. volume | 259,743 |
| 50-day MA | $11.33 | Dividend yield | N/A |
| 200-day MA | $18.78 | Market Cap | 378.01M |
Monte Rosa Therapeutics, Inc. (GLUE) Company Bio
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.
Latest GLUE News From Around the Web
Below are the latest news stories about Monte Rosa Therapeutics Inc that investors may wish to consider to help them evaluate GLUE as an investment opportunity.
Monte Rosa Therapeutics Announces Participation in Upcoming Investor ConferencesBOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is scheduled to present at the following upcoming investor conferences: Guggenheim Oncology Conference Virtual Fireside Chat 3:00 p.m. ET, Thursday, February 10 11th Annual SVB Leerink Global Healthcare Conference Virtual Fireside Chat 8:00 a.m. ET, Friday, February 18 Cowen’s 42nd Annual Health Care C |
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue DegradersBOSTON and REHOVOT, Israel, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, announced a license and research collaboration agreement with Dr. Nir London and the Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science, which aims to accelerate the discovery and development of novel covalent molecular glue degraders leveraging CoLDR (covalent ligan |
Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceBOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference at 5:15 p.m. ET on Tuesday, January 11, 2022. An archived webcast of the presentation can be accessed for up to 30 days via the “Events & Presentations” section of the company’s investor site at https://ir.monterosatx. |
Reviewing Monte Rosa Therapeutics (NASDAQ:GLUE) and Ocugen (NASDAQ:OCGN)Monte Rosa Therapeutics (NASDAQ:GLUE) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Analyst Recommendations This is a breakdown of recent recommendations and price targets for Monte Rosa [] |
Ocugen (NASDAQ:OCGN) and Monte Rosa Therapeutics (NASDAQ:GLUE) Head to Head AnalysisMonte Rosa Therapeutics (NASDAQ:GLUE) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership. Insider and Institutional Ownership 28.5% of Ocugen shares are held by institutional investors. 3.7% of [] |
GLUE Price Returns
| 1-mo | -27.29% |
| 3-mo | -46.29% |
| 6-mo | -57.92% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -60.33% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...